Stapler and staple line reinforcement material

Information

  • Patent Grant
  • 11771430
  • Patent Number
    11,771,430
  • Date Filed
    Tuesday, February 18, 2020
    4 years ago
  • Date Issued
    Tuesday, October 3, 2023
    a year ago
Abstract
A surgical stapling instrument includes a staple cartridge assembly having a plurality of rows of staple receiving slots and an anvil assembly having a plurality of rows of staple forming recesses. The staple cartridge assembly, the anvil assembly, or both have one or more attachment members overmolded thereon. A staple line reinforcement material is attached to the attachment members.
Description
BACKGROUND
1. Technical Field

The present application relates to surgical stapling and staple line reinforcement materials. In particular, the staple line reinforcement material is attached to one or both tissue contacting surfaces of a surgical stapler utilizing a retainer.


2. Background

The use of staple line reinforcement materials, or buttresses, in conjunction with staplers is known. U.S. Pat. No. 5,542,594 to McKean et al., the disclosure of which is hereby incorporated by reference herein, discloses a surgical stapling apparatus with a biocompatible surgical fabric attached to the apparatus. The surgical fabric and staples are attached to body tissue by the stapling apparatus. Pins or clips secure the fabric to surfaces of the stapling apparatus.


U.S. Pat. No. 7,128,748 discloses a circular stapler and buttress. The buttress material is positioned on the staple cartridge of the stapler and on the anvil component of the stapler. The anvil buttress material has a cylindrical raised center portion adapted to fit the central recessed aperture of the anvil and the staple cartridge buttress has a cylindrical raised center portion adapted to fit a central recessed aperture in the cartridge component of the stapler.


U.S. Pat. No. 6,503,257 discloses an adhesive used to releasably attach a buttress material to clamping members of a stapler. The buttress material is releasably attached by the adhesive material.


There is a need for a staple line reinforcement material or buttress material attachment that does not complicate assembly or manufacturing, does not interfere with the operation of the surgical instrument, and securely attaches the material while allowing the material to be reliably released when desired.


SUMMARY

In an aspect of the present disclosure, a surgical stapling instrument comprises a staple cartridge assembly having a plurality of rows of staple receiving slots, an anvil assembly having an anvil member defining a plurality of rows of staple forming recesses. The staple cartridge assembly, the anvil assembly, or both, has one or more attachment members. A staple line reinforcement material is attached to the attachment members by ultrasonic welding.


In certain embodiments, the staple line reinforcement material defines perforations adjacent the attachment members. Such perforations can be useful to facilitate release of the buttress from the surgical stapling apparatus. In certain embodiments, the surgical stapling instrument is a circular stapler. The plurality of rows of staple receiving slots can be circular rows. Such staplers are useful in intestinal anastomosis procedures and other surgical procedures. The plurality of rows of staple forming recesses can be circular rows.


In certain embodiments, the one or more attachment members are formed on the anvil member by molding plastic. The one or more attachment members can be disposed on the anvil member; the anvil member is made of metal, whereas the attachment members can made from plastic.


In certain embodiments, the one or more attachment members are disposed on the staple cartridge assembly outwardly of the rows of staple receiving slots. The staple line reinforcement material can be attached to the one or more attachment members and define perforations adjacent the one or more attachment members. In this way, the staple line reinforcement material lifts away from the staple cartridge assembly, separating at the perforations. A margin of material remains on the staple cartridge assembly.


In another arrangement, the one or more attachment members are disposed on the anvil assembly outwardly of the rows of staple forming recesses. The staple line reinforcement material is attached to the one or more attachment members and defines perforations adjacent the one or more attachment members.


The anvil assembly may include a hub attached to the anvil member. The anvil assembly may include a shaft and further comprising a tubular body portion, the staple cartridge assembly being mountable in the tubular body portion; the tubular body portion has a rod, the shaft of the anvil assembly being attachable to the shaft. The surgical stapling instrument, in certain embodiments, comprises a handle assembly.


In another aspect of the present disclosure, a surgical stapling instrument comprises a staple cartridge assembly having a plurality of rows of staple receiving slots, an anvil assembly having a shaft and an anvil member; the anvil member defines a plurality of rows of staple forming recesses. A retainer is engaged to the shaft, and a staple line reinforcement material attached to the anvil assembly by the retainer.


The surgical stapling instrument can be a circular stapler. The plurality of rows of staple receiving slots can be circular rows, whereas the plurality of rows of staple forming recesses would be circular rows.


In certain embodiments, the retainer is circular in shape and has a central aperture for receiving the shaft. The retainer may be frictionally engaged with the shaft. For example, the retainer is formed of a material that has a coefficient of friction with the shaft, the coefficient of friction being selected so as to retain the retainer and the staple line reinforcement material on the shaft.


In certain embodiments, the retainer is secured to the shaft utilizing a fastener. Alternatively, the retainer is secured to the shaft utilizing a snap-fit relationship between the retainer and the anvil assembly. The retainer, the shaft, or both, may be texturized in such a way so as to improve the frictional engagement of those parts. For example, the surface of the shaft is mechanically treated, or the shaft, the retainer, or both, have a coating that increases friction between the shaft and the retainer.


The anvil assembly may include a hub attached to the anvil member. In certain embodiments, the surgical stapling instrument has a tubular body portion, the staple cartridge assembly being mountable in the tubular body portion; the tubular body portion has a rod, the shaft of the anvil assembly being attachable to the shaft. In certain embodiments, the surgical stapling instrument has a handle assembly.





BRIEF DESCRIPTION OF THE DRAWINGS

An embodiment or embodiments of the presently disclosed surgical instrument and staple line reinforcement material is disclosed with reference to the drawings, wherein:



FIG. 1 is a perspective view of an embodiment of the present disclosure showing including a circular stapling instrument;



FIG. 2 is perspective view of the circular stapling instrument of FIG. 1 with the anvil assembly detached;



FIG. 3 is a perspective view of the circular stapling instrument of FIGS. 1 and 2 with the anvil assembly attached;



FIG. 4 is a perspective view of a circular stapling instrument anvil assembly, staple line reinforcement material, and retainer, with parts separated, according to the embodiment of FIGS. 1 through 3;



FIG. 5 is an elevation view of a staple line reinforcement material retainer assembly according to the embodiment of FIGS. 1 through 4;



FIG. 6 is a staple line reinforcement material retainer assembly according to a further embodiment of the present disclosure;



FIG. 7 is a plan view of a prior art circular stapling instrument anvil member;



FIG. 8 is a plan view of a circular stapling instrument anvil member according to a further embodiment of the present disclosure;



FIG. 9 is a detail of FIG. 7 showing attachment tabs;



FIG. 10 is a plan view of a ring having attachment member tabs in accordance with a further embodiment of the present disclosure;



FIG. 11 is a partial perspective view of a circular stapling instrument body portion and cartridge assembly in accordance with another embodiment;



FIG. 12 is a plan view of a ring having attachment member tabs in accordance with the embodiment of FIG. 11;



FIG. 13 is a perspective view of a staple line reinforcement material in accordance with a further embodiment of the present disclosure;



FIG. 14 is perspective view of a linear surgical stapling instrument according to another embodiment of the present disclosure;



FIG. 15 is a perspective view of a staple cartridge assembly in accordance with the embodiment of FIG. 14;



FIG. 16 is a perspective view of an anvil member in accordance with the embodiment of FIGS. 14 through 15;



FIG. 17 is a perspective view of a staple line reinforcement material in accordance with the embodiment of FIGS. 14 through 16;



FIG. 18 is a plan view of a ring or frame having attachment member tabs in accordance with the embodiment of FIGS. 14 through 17;



FIG. 19 is a perspective view of a staple line reinforcement material in accordance with an embodiment of the present disclosure; and



FIG. 20 is a perspective view of a staple line reinforcement material in accordance with a further embodiment of the present disclosure.





DETAILED DESCRIPTION

An embodiment or embodiments of the presently disclosed stapling instrument, retainer, and staple line reinforcement material will now be described in detail with reference to the drawings. Like numerals in the drawings designate identical or corresponding elements in each of the several views. As is common in the art, the term “proximal” refers to that part or component that is closer to the user of the instrument while the term “distal” refers to that part or component that is farther from the user of the instrument.



FIG. 1 illustrates a circular surgical stapling instrument which is generally designated as 10. Surgical stapling instrument 10 includes a handle assembly 12 having at least one pivotable actuating handle 14 and a rotatable actuator 18. A tubular body portion 20 extends from the handle assembly 12. The tubular body portion 20, which generally has a circular cross-sectional shape, may have a straight or a curved shape along its length and may be flexible or relatively rigid. Cross-sectional shapes other that circular are contemplated, so that the tubular body portion 20 can have a polygonal, elliptical, semi-circular, ovoid, or other shape. The body portion 20 terminates in a staple cartridge assembly 22 which includes a distally facing tissue contacting surface defining one or more rows 37 of staple receiving slots 36. Each staple receiving slot has a staple (not shown) disposed therein. Typically, a pair of circular rows 37 of staple receiving slots 36 is provided, although other shapes, such as annular, are contemplated. An anvil assembly 30 is positioned distally of the staple cartridge assembly 22, which includes an anvil member 26 and an anvil shaft 28 operatively associated therewith. The anvil assembly has a proximally facing tissue contacting surface that defines staple forming recesses 27 that correspond to the circular rows of staple receiving slots. The tubular body portion 20 has a corresponding rod or shaft 40 centrally located with respect to the staple cartridge assembly 22. The shaft 28 of the anvil assembly is removably connectable to the rod or shaft 40 of the tubular body portion 20. The anvil shaft defines a longitudinal axis “x”.


The staple cartridge assembly 22 is connectable to the distal end of tubular body portion 20 or may be configured to concentrically fit within the distal end of tubular body portion 20. Typically, staple cartridge assembly 22 includes a staple pusher (not shown) with a distal portion defining two concentric rings of peripherally spaced fingers (not shown), each one of which is received within a respective staple receiving slot 36. Typically, a knife (not shown) having a cutting edge is disposed within the staple cartridge assembly 22. The knife edge is circular and disposed radially inward of the rows of staples. The knife is mounted so that as the staple pusher is advanced axially in the direction of the anvil assembly, the knife is also advanced axially. Alternatively, the knife may be separately actuated. The staple pusher is advanced in the distal direction to drive staples from the staple receiving slots 36 against the anvil member so that the staple forming recesses 27 form the staples in a closed shape. The knife is advanced and driven toward the anvil assembly 30 to cut tissue. U.S. Pat. No. 5,915,616 to Viola et al., the entire content of which is hereby incorporated herein by reference, discloses a circular stapling instrument. Although a circular stapling instrument is shown in FIG. 1, the stapling device may be arranged to deploy staples in a semi-circular, linear, or other desired shape. Although discussed with reference to intestinal tissue, devices according to the present disclosure can be arranged to join and/or treat other tissues in other procedures.


The anvil member 26 may or may not be pivotable about the anvil shaft 28 from a first, initial position in which a plane defined by the tissue contact surface 52 of the anvil member 26 is substantially perpendicular to the longitudinal axis of the anvil shaft 28 to a second position, tilted with respect to the longitudinal axis “x”. The second position is desirably a reduced profile position in which anvil member 26 defines an angle with respect to the longitudinal axis “x”. Alternately, the anvil member 26 is rigidly attached to the anvil shaft 28.


The anvil shaft 28 is dimensioned to releasably engage an anvil retainer (not shown) on the rod or shaft 40 of a circular surgical stapling instrument, such as the surgical stapling instrument 10. One such surgical stapling device having an anvil retainer and with which anvil assembly 30 may be used is disclosed in U.S. provisional patent application Ser. No. 60/281,259, filed Apr. 3, 2001, (“the '259 application”) which is hereby incorporated by reference herein, in its entirety. The anvil retainer functions to align anvil assembly 30 with the body portion 20 (FIG. 1) of the surgical stapling instrument 10 during movement of the anvil assembly 30 from a positioned spaced from the staple cartridge assembly 22 of the surgical stapling device to an approximated position in close alignment with the staple cartridge assembly 22.


The circular stapling instrument can be used to form an anastomosis between sections of intestinal tissue. As shown in FIGS. 2 and 3, the anvil assembly 30 is detached from the rod or shaft 40 of the tubular body portion 20 and a section of tubular body vessel, such as a section of intestine, is secured to the anvil assembly 30, typically by tying a suture “P” around the shaft 28 of the anvil assembly 30. Another section of tubular tissue is secured to the tubular body portion 20 by tying a suture around the shaft 40. See FIG. 2. The shaft 28 is then connected to the shaft 40. The actuator 18 is rotated to withdraw the shafts 28, 40 thereby approximating the anvil assembly 30 with the staple cartridge assembly 22. To fire the staples, the actuating handles 14 are squeezed, which advances the staple pusher and the knife (not shown). The staples pass through each section of tubular tissue and are formed against the anvil so that the sections of tubular tissue are joined to one another. The knife cuts the tissue radially inward of the rows of staples, and the sutured material is removed with the circular stapling device.


According to the present disclosure, a surgical stapling instrument has a staple line reinforcement material retained thereon. In certain embodiments, the anvil head 42 has an inner recess 53 that is generally annular and may include a cut ring for receiving the knife. As shown in FIG. 4, a staple line reinforcement material 50 has a central aperture 51 for receiving the anvil shaft 28 and is dimensioned so that the staple line reinforcement material overlies the staple forming recesses 27 of the anvil member 26 when the staple line reinforcement material is placed on the shaft 28. A small amount of excess material may lie over the outside edge of the anvil member. A retainer 60, which may be shaped as a washer with a central aperture 61, has an outside diameter slightly less than the inside diameter of the knife so that the retainer does not interfere with cutting. The inside diameter is dimensioned to receive the anvil shaft and be frictionally retained on the shaft. FIG. 5 shows the staple line reinforcement material retainer assembly 66. When the staple line reinforcement material is placed on the anvil shaft 28 and the retainer 60 is then placed on the anvil shaft 28 over the staple line reinforcement material, the frictional engagement between the retainer 60 and the shaft keep the staple line reinforcement material in place during use. The retainer 60 may be formed of a material that has a desired coefficient of friction with the shaft, which is normally metal, such as stainless steel.


In another embodiment, the retainer is secured to the anvil assembly utilizing a fastener (such as a screw or bolt), a clip, a detent, or by a snap-fit relationship between the retainer and the anvil assembly. In a further alternative, the retainer 60, the shaft 28, or both, may be texturized 69, 29, respectively, in such a way so as to improve the frictional engagement of those parts. This can include mechanically treating the surfaces of the shaft and/or retainer, or can include coatings.


During use, the rotatable actuator 18 is manipulated to approximate the anvil assembly 30 toward the staple cartridge assembly 22 and clamp tissue therebetween. When the pivotable actuating handle 14 is moved, the knife and/or pusher will be moved in a direction toward the anvil assembly to fire the staples and cut tissue. The staple line reinforcement material retainer assembly 66 is arranged so that the retainer 60 lies inwardly of the knife. The retainer retains the staple line reinforcement material 50 against the tissue contacting surface 52 of the anvil member 26. The knife will cut the tissue and the staple line reinforcement material, making the retainer easy to remove with the circular stapling instrument 10.


In another embodiment of the present disclosure, a circular stapling instrument as discussed above in connection with FIGS. 1 through 3 has an anvil assembly 130 with an anvil member 126 attached to an anvil head 142. The anvil assembly 130 further includes an anvil shaft 128 attachable to the rod or shaft 40. A typical prior art anvil member 125 is shown in FIG. 7 and has two rows of staple forming recesses 127 formed in the tissue contact surface 152 of the anvil member 125. An anvil member 126 according to an embodiment of the present disclosure is shown in FIG. 8. Attachment members 132, which may be formed as tabs, are attached to the anvil member 126 so that the attachment members 132 are generally flush with the tissue contact surface 152. Recessed or protruding attachment members are also contemplated. In this way, the anvil member 126 can be formed from a material that is useful for defining staple forming recesses therein and for forming staples. Thus, typically the anvil member is formed from a metal such as stainless steel. The attachment members 132 are formed from a material that is useful for attachment to a staple line reinforcement material. The staple line reinforcement material 50 is attached to the attachment members utilizing adhesives, ultrasonic or other kinds of welding, or other methods. The attachment member or members 132 may be formed of a variety of polymeric materials, such as the polymeric materials from which the staple line reinforcement material is made. In one example, recesses are formed in the anvil member, as by grinding, drilling, machining, etc. A polymeric material is overmolded on the anvil member so that attachment members of the polymeric material are disposed in the recesses. In a further embodiment, a plastic frame or ring 141 having tabs extending inwardly (see FIG. 10) is attached to the anvil member, either before or after the assembly of the anvil member 126 with the anvil head 142. The tabs are snapped into place in preformed recesses in the anvil member. Alternately, the frame or ring 141 is attached to the anvil member so that the tab or tabs are disposed adjacent the tissue contact surface 152 but outside of the staple forming recesses 127. In another embodiment, the plastic ring may be used, without tabs, so that the staple line reinforcement material is attached at the ring.


One or more attachment members 132 may be used and they may have a variety of shapes. The tabs shown in FIG. 9 are generally trapezoidal in shape and are disposed between the staple forming recesses of the anvil member as shown in FIG. 8. The attachment members/tabs do not interfere with the formation of the staples in the staple receiving recesses.


It may be desirable to attach a staple line reinforcement material 50 adjacent the staple cartridge assembly 22. As shown in FIG. 11, the staple cartridge assembly 22 has a central recess 24 through which the rod or shaft 40 (which has been omitted for clarity) passes. An attachment member or attachment members 232, which may be formed as tabs, are attached to the tissue contact surface 25 of the cartridge assembly 22. The attachment members 232 may be formed so that they are generally flush with the tissue contact surface 25, but recessed or protruding attachment members are contemplated. The attachment member or members are formed from a material useful for attachment to the staple line reinforcement material. The staple line reinforcement material 50 is attached to the attachment members utilizing adhesives, ultrasonic or other kinds of welding, or other methods. The attachment members 232 may be formed from a variety of polymeric materials, such as the polymeric materials from which the staple line reinforcement material is made. In one example, recesses are formed in the staple cartridge tissue contact surface 25 and a polymeric material is overmolded on the staple cartridge in the recesses. In this way, the material of the staple cartridge can be different from the material for attaching the staple line reinforcement material. In other embodiment, a plastic frame or ring 241 (FIG. 11) having tabs extending inwardly is attached to the staple cartridge so there the tabs are snapped into place in preformed recesses. Alternately, the frame or ring 241 is attached to the cartridge assembly or to the body portion 20 so that the tab or tabs are disposed on the tissue contact surface 25 but lie outwardly of the staple slots 36. In another embodiment, the plastic ring may be used, without tabs, so that the staple line reinforcement material is attached at the ring.


Alternately, the material of the staple cartridge 23, which is normally plastic, can be selected so as to be useful for attaching the staple line reinforcement material by adhesives, ultrasonic or other kinds of welding, or other methods. In certain embodiments, the anvil assembly 130 includes a cut ring disposed in the recess 153. The cut ring can be formed with tabs extending proximally toward the tissue contact surface 152 so as to be accessible for attachment to the staple line reinforcement material.


In the embodiments discussed in connection with FIGS. 6 through 12, the staple line reinforcement material 50 can be dimensioned to have an inner diameter that is smaller than the diameter of the knife of the circular stapling instrument. When the knife is actuated, a portion of the staple line reinforcement material is removed. This may tend to increase the firing forces for the circular stapling instrument. Alternately, the staple line reinforcement material 50 can be dimensioned to have an inner diameter that is larger than the diameter of the knife of the circular stapling instrument so that the knife does not cut the staple line reinforcement material. When the staple firing is actuated, the staples hit the staple line reinforcement material, passing through the staple line reinforcement material. The staples that impact near the weld or other attachment points apply enough force to substantially break the connection between the staple line reinforcement material and the attachment member or attachment members. The staple line reinforcement material is thereby released. Alternately, the gentle manipulation of the circular stapling instrument can be relied upon to gently separate the staple line reinforcement material from the attachment points.


In another embodiment of the present disclosure, a surgical stapling instrument and staple line reinforcement material according to FIGS. 1 through 3 and 6 through 12 has a staple line reinforcement material 50a attached to an attachment member or attachment members 132 disposed at the tissue contacting surface 52 of the anvil assembly and/or disposed at the tissue contact surface 25 of the staple cartridge assembly 22. The attachment member or members 132 are formed from a material that is useful for attaching the staple line reinforcement material 50a. The staple line reinforcement material 50a is attached to the attachment member or attachment members 132 permanently, so that the material 50 is not intended to be releasable when the staples are fired or the instrument is manipulated in removing the instrument from the surgical site. The staple line reinforcement material includes perforations 68, or areas of weakness, adjacent the attachment member or members. See FIG. 19. The inner diameter of the staple line reinforcement material 50a is larger than the diameter of the knife. Desirably, the attachment member or attachment members 132 lie outwardly of the staple forming recesses 27 of the anvil assembly 30 and/or outwardly of the staple receiving slots 36 of the staple cartridge assembly 22. The perforations 68 are disposed inwardly of the attachment member or members 132, but outwardly of the knife. In use, the anvil assembly will be approximated with the staple cartridge assembly to clamp tissue, and the staples will be fired and the knife deployed. Upon removal of the stapling instrument, the staple line reinforcement material 50a will separate from the anvil assembly and/or cartridge assembly at the perforations. A margin of material will remain with the anvil assembly and/or cartridge assembly.


In another embodiment, the staple line reinforcement material 50a has an inner diameter that is smaller than the diameter of the knife so that a portion of the staple line reinforcement material 50a is severed removed by the knife.


In another embodiment of the present disclosure a linear stapling instrument is used with a staple line reinforcement material on the anvil, the cartridge assembly, or both. The linear stapling instrument 300 has stapler jaws 310, 320. See FIG. 14. The stapler jaw 310 is a staple cartridge assembly having one or more rows 337 of staple receiving slots 336. Each staple receiving slot has a staple (not shown) disposed therein. Typically, three linear rows 337 of staple receiving slots 336 are provided on either side of a channel 339. The other jaw is an anvil assembly 320 positioned in opposition to the staple cartridge assembly 310 and pivotably mounted so that the anvil assembly and staple cartridge assembly can be approximated to clamp tissue therebetween. The anvil assembly includes an anvil member 326 defining a plurality of staple forming recesses 331 that correspond to the linear rows 337 so that the stapling instrument forms linear staple lines. The stapling jaws 310, 320 are disposed at a distal end of an endoscopic shaft 340. A handle assembly 301 includes a pivotable handle 303 that drives movement of a drive member through the staple cartridge assembly 310. The drive member (not shown) passes through the channel 339 and pushes a sled or camming bar through the staple cartridge to drive staple pushers, and the staples, through the slots 336 toward the staple forming recesses of the anvil member 326. Certain embodiments of such a surgical instrument is disclosed in U.S. Pat. No. 6,241,139 to Milliman et al., the disclosure of which is hereby incorporated by reference herein, in its entirety.


To attach the staple line reinforcement material to the jaw or jaws 310, 330, attachment members are formed on or in the cartridge assembly 310 and/or anvil assembly 330. Typically the anvil member 326 is formed from a metal such as stainless steel. The attachment members 332 are formed from a material that is useful for attachment to a staple line reinforcement material. The staple line reinforcement material 350 is attached to the attachment members 332 utilizing adhesives, ultrasonic or other kinds of welding, or other methods. The attachment member or members 332 may be formed of a variety of polymeric materials, such as the polymeric materials from which the staple line reinforcement material is made. In one example, recesses are formed in the anvil member, as by grinding, drilling, machining, etc. A polymeric material is overmolded on the anvil member so that attachment members of the polymeric material are disposed in the recesses. In one embodiment, the attachment members 332 include a first distal attachment member 332a, a second distal attachment member 332b, a first proximal attachment member 332c, and a second proximal attachment member 332d, so that there are one or more attachment members at each of the distal and proximal ends of the anvil member. See FIG. 16.


In a further embodiment, a plastic frame or ring 341 having tabs 342 extending inwardly (see FIG. 18) is attached to the anvil member, either before or after the assembly of the anvil member 326 in the anvil assembly. The tabs are snapped into place in preformed recesses in the anvil member. Alternately, the frame or ring 341 is attached to the anvil member so that the tab or tabs are disposed adjacent the tissue contact surface 352 but outside of the staple forming recesses 327. In another embodiment, the plastic frame or ring may be used, without tabs, so that the staple line reinforcement material is attached at the ring.


It may be desirable to attach a staple line reinforcement material to the tissue contact surface 311 of the cartridge assembly 310. Attachment members 334 are provided for the staple cartridge assembly and are formed from a material that is useful for attachment to a staple line reinforcement material. The staple line reinforcement material 350 is attached to the attachment members 334 utilizing adhesives, ultrasonic or other kinds of welding, or other methods. The attachment member or members 334 may be formed of a variety of polymeric materials, such as the polymeric materials from which the staple line reinforcement material is made. The attachment member or members 334 can be made by providing recesses in the tissue contact surface 311 of the cartridge assembly 310, and overmolding. Alternately, a plastic frame or ring, like that shown in FIG. 18 may or may not include tabs and provides a surface at which to attach the staple line reinforcement material using adhesives, ultrasonic or other welding, and other methods. Alternatively, the material of the staple cartridge can be selected so as to be useful for attaching the staple line reinforcement material.


In another embodiment of the present disclosure, a surgical stapling instrument and staple line reinforcement material according to FIGS. 14 through 18 has a staple line reinforcement material 350A attached to an attachment member or attachment members 332 disposed at the tissue contacting surface of the anvil assembly 320 and/or attachment member or members 334 disposed at the tissue contact surface of the staple cartridge assembly 310. The attachment member or members 332, 334 are formed from a material that is useful for attaching the staple line reinforcement material 350A. The staple line reinforcement material 350A is attached to the attachment member or attachment members 332, 334 permanently, so that the material 350A is not intended to be releasable when the staples are fired or the instrument is manipulated in removing the instrument from the surgical site. The staple line reinforcement material includes perforations 368, or areas of weakness, adjacent the attachment member or members 332, 334. See FIG. 20. Desirably, the attachment member or attachment members 332, 334 lie outwardly of the rows 337 of staple forming recesses 331 of the anvil assembly 30 and/or outwardly of the rows 337 of the staple receiving slots 336 of the staple cartridge assembly 310. The perforations are disposed inwardly of the attachment member or members 332, 334, but outwardly of the rows 337 staple forming recesses 331 of the anvil assembly 30 and/or outwardly of the rows 337 of the staple receiving slots 336. In use, the anvil assembly will be approximated with the staple cartridge assembly to clamp tissue, and the staples will be fired and the knife deployed. Upon removal of the stapling instrument, the staple line reinforcement material 350A will separate from the anvil assembly and/or cartridge assembly at the perforations. A margin of staple line reinforcement material remains with the surgical stapling instrument.


It is contemplated that the staple line reinforcement materials discussed above may be fabricated from or include a surgical grade, biocompatible, non-absorbable material and may comprise a mesh. For example, the staple line reinforcement material may be fabricated from “TEFLON”, which is a registered trademark owned by DuPont de Nemours & Co. It is further contemplated that body portion 102 may be fabricated from a biocompatible polymeric foam, felt, polytetrafluoroethylene (ePTFE), gelatin, fabric or the like, or any other biocompatible material.


Non-absorbable materials used for staple line reinforcement material include, and are not limited to, those that are fabricated from such polymers as polyethylene, polypropylene, nylon, polyethylene terephthalate, polytetrafluoroethylene, polyvinylidene fluoride, and the like. Further non-absorbable materials include and are not limited to stainless steel, titanium and the like.


In one embodiment, the staple line reinforcement material may be fabricated from a bio-absorbable material. In other embodiments, the staple line reinforcement material has at least one portion that is absorbable and at least one portion that is not absorbable. Bio-absorbable materials used for staple line reinforcement material include, and are not limited to, those fabricated from homopolymers, copolymers or blends obtained from one or more monomers selected from the group consisting of glycolide, glycolic acid, lactide, lactic acid, p-dioxanone, α-caprolactone and trimethylene carbonate. Other bio-absorbable materials include and are not limited to, for example, Polyglycolic Acid (PGA) and Polylactic Acid (PLA). In one embodiment, the staple line reinforcement material may be fabricated from bio-absorbable felt, gelatin or any other bio-absorbable materials.


The staple line reinforcement material can incorporate a wound treatment material, which includes and is not limited to one or a combination of adhesives, hemostats, sealants, coagulants, astringents, and medicaments. Other surgically biocompatible wound treatment materials which may be employed in or applied by surgical instruments, including surgical staplers, include adhesives whose function is to attach or hold organs, tissues or structures; sealants to prevent fluid leakage; hemostats to halt or prevent bleeding; coagulants, astringents (e.g., sulfates of aluminum) and medicaments. Examples of adhesives which can be employed include protein derived, aldehyde-based adhesive materials, for example, the commercially available albumin/glutaraldehyde materials sold under the trade designation BioGlue™ by Cryolife, Inc., and cyanoacrylate-based materials sold under the trade designations Indermil™ and Derma Bond™ by Tyco Healthcare Group, LP and Ethicon Endosurgery, Inc., respectively. Examples of sealants, which can be employed, include fibrin sealants and collagen-based and synthetic polymer-based tissue sealants. Examples of commercially available sealants are synthetic polyethylene glycol-based, hydrogel materials sold under the trade designation CoSeal™ by Cohesion Technologies and Baxter International, Inc. Examples of hemostat materials, which can be employed, include fibrin-based, collagen-based, oxidized regenerated cellulose-based and gelatin-based topical hemostats. Examples of commercially available hemostat materials are fibrinogen-thrombin combination materials sold under the trade designations CoStasis™ by Tyco Healthcare Group, LP, and Tisseel™ sold by Baxter International, Inc. The wound treatment material can include medicaments. Medicaments may include one or more medically and/or surgically useful substances such as drugs, enzymes, growth factors, peptides, proteins, dyes, diagnostic agents or hemostasis agents, monoclonal antibodies, or any other pharmaceutical used in the prevention of stenosis.


The staple line reinforcement material may include a single layer including a homogeneous array of bio-absorbable or non-absorbable materials or a heterogeneous array of bio-absorbable and/or non-absorbable materials. The staple line reinforcement material may include a layered body portion having at least two layers as indicated by first layer, film or wafer and second layer, film or wafer. In this embodiment, each layer may include a homogeneous or heterogeneous array of bio-absorbable and/or non-absorbable materials.


In certain preferred embodiments, the staple line reinforcement material is a non-woven fabric. The non-woven fabric can be formed utilizing a melt blown process, including the following steps. The polymer resin is melt extruded. A melt pump meters out the molten polymer to a die head having an array of holes. By way of example, the holes have a diameter of between about 0.175 and about 0.25 millimeters. The polymer is forced through the array of holes in the die. Polymer fibers exit the die and are forced onto a conveyor belt. A stream of blowing hot air can be used to force the polymer fibers onto the conveyor. Suction through the conveyor belt surface can be used to compact the fibers against the belt and against each other, as the fibers cool. Additional compression may be applied to the fibers, such as by using a calendaring roll, which may include heating or cooling. The non-woven fabric may then be annealed. For example, isometric tension or other uniform compression can be used to drive crystallization and remove the monomer. The polymer is desirably a bioabsorbable or non-bioabsorbable polymer, such as a glycolide lactide copolymer (the material utilized in Polysorb™ sutures), a termpolymer composed of glycolide, trimethylene carbonate and dioxanone (the material utilized in Biosyn™ sutures), a polymer of glycolide, caprolactone, trimethylene carbonate, and lactide (the material utilized in Caprosyn™ sutures), and a glycolide trimethylene carbonate copolymer (the material utilized in Maxon™ sutures).


In certain embodiments, the non-woven fabric is porous. For example, the non-woven fabric can have a porosity of between about 50% and about 90%. The fiber diameter may be between about 5 and about 100 μm. The fabric thickness may be between about 150 and about 400 μm.


It will be understood that various modifications may be made to the embodiments disclosed herein. For example, the surgical stapling instrument need not apply staples but rather may apply two part fasteners as is known in the art. Further, the length of the linear row of staples or fasteners, or the length or diameter of a circular row of staples or fasteners, may be modified to meet the requirements of a particular surgical procedure. Therefore, the above description should not be construed as limiting, but merely as exemplifications of preferred embodiments. Those skilled in the art will envision other modifications within the scope and spirit of the claims appended thereto.

Claims
  • 1. A surgical stapling instrument, comprising: an anvil assembly having a tissue contacting surface defining a plane and a plurality of longitudinally-extending rows of staple forming recesses therein;a staple cartridge assembly having a tissue contacting surface defining a plane and a plurality of longitudinally-extending rows of staple receiving slots therein;a staple line reinforcement material supported on the tissue contacting surface of at least one of the staple cartridge assembly or the anvil assembly, the staple line reinforcement material defining a first portion and a second portion surrounding the first portion;first and second elongate attachment members supported on the tissue contacting surface of at least one of the staple cartridge assembly or the anvil assembly, the first elongate attachment member being disposed at a distal end portion of the at least one of the staple cartridge assembly or the anvil assembly and defining a longitudinal axis that is transverse relative to a longitudinal axis defined by a first row of the plurality of rows of staple forming recesses or a first row of the plurality of rows of staple receiving slots, andthe second elongate attachment member being disposed at a proximal end portion of the at least one of the staple cartridge assembly or the anvil assembly and defining a longitudinal axis that is aligned with the longitudinal axis of the first row of the plurality of rows of staple forming recesses or the first row of the plurality of rows of staple receiving slots; andan adhesive interposed between each of the first and second attachment members and the staple line reinforcement material, wherein the adhesive permanently attaches the first and second attachment members to the first portion of the staple line reinforcement material and prohibits the first portion of the staple line reinforcement material from releasing from the tissue contacting surface of at least one of the staple cartridge assembly or the anvil assembly during a staple firing,wherein the staple line reinforcement material includes a plurality of perforations configured to facilitate separation of the second portion of the staple line reinforcement material from the first portion of the staple line reinforcement material at the plurality of perforations,wherein the longitudinal axis of each of the first and second elongate attachment members is parallel with the plane of the tissue contacting surface of the at least one of the staple cartridge assembly or the anvil assembly.
  • 2. The surgical stapling instrument according to claim 1, further comprising a third elongate attachment member disposed at the proximal end portion of the at least one of the staple cartridge assembly or the anvil assembly and defining a longitudinal axis that is parallel with the longitudinal axis of the first row of the plurality of rows of staple forming recesses or the first row of the plurality of rows of staple receiving slots.
  • 3. The surgical stapling instrument according to claim 2, wherein the second and third elongate attachment members are spaced from one another along a transverse axis extending perpendicularly relative to the longitudinal axis of the first row of the plurality of rows of staple forming recesses or the first row of the plurality of rows of staple receiving slots.
  • 4. The surgical stapling instrument according to claim 3, wherein the second elongate attachment member is disposed adjacent a first lateral side of the at least one of the staple cartridge assembly or the anvil assembly, and the third elongate attachment member is disposed adjacent a second lateral side of the at least one of the staple cartridge assembly or the anvil assembly.
  • 5. The surgical stapling instrument according to claim 2, further comprising a fourth elongate attachment member disposed at the distal end portion of the at least one of the staple cartridge assembly or the anvil assembly and defining a longitudinal axis that is parallel with the longitudinal axis of the first row of the plurality of rows of staple forming recesses or the first row of the plurality of rows of staple receiving slots.
  • 6. The surgical stapling instrument according to claim 5, wherein the first and fourth elongate attachment members are spaced from one another along a transverse axis extending perpendicularly relative to the longitudinal axis of the first row of the plurality of rows of staple forming recesses or the first row of the plurality of rows of staple receiving slots.
  • 7. The surgical stapling instrument according to claim 1, wherein the first elongate attachment member has a width that is parallel with the longitudinal axis of the first row of the plurality of rows of staple forming recesses or the first row of the plurality of rows of staple receiving slots, and wherein the second elongate attachment member has a width that is transverse relative to the longitudinal axis of the first row of the plurality of rows of staple forming recesses or the first row of the plurality of rows of staple receiving slots.
  • 8. A surgical stapling instrument, comprising: an anvil assembly having a tissue contacting surface defining a plurality of rows of staple forming recesses therein, wherein adjacent staple forming recesses in a first row of the plurality of rows of staple forming recesses define a gap therebetween, the first row of the plurality of rows of staple forming recesses defines an annular axis;a staple cartridge assembly having a tissue contacting surface defining a plurality of rows of staple receiving slots therein, wherein adjacent staple receiving slots in a first row of the plurality of rows of staple receiving slots define a gap therebetween, the first row of the plurality of rows of staple receiving slots defines an annular axis;a staple line reinforcement material having a top surface, and an opposite bottom surface supported on the tissue contacting surface of at least one of the staple cartridge assembly or the anvil assembly, the staple line reinforcement material defining a first portion and a second portion surrounding the first portion;a plurality of attachment members disposed in respective gaps of the first row of staple forming recesses and on the annular axis of the first row of the plurality of rows of staple forming recesses or in respective gaps of the first row of staple receiving slots and on the annular axis of the first row of the plurality of rows of staple receiving slots, wherein the plurality of attachment members are positioned on the tissue contacting surface of at least one of the staple cartridge assembly or the anvil assembly; andan adhesive interposed between the plurality of attachment members and the staple line reinforcement material, wherein the adhesive permanently attaches the plurality of attachment members to the bottom surface of the first portion of the staple line reinforcement material to secure the bottom surface of the staple line reinforcement material to the tissue contacting surface of at least one of the staple cartridge assembly or the anvil assembly and prohibit the first portion of the staple line reinforcement material from releasing from the tissue contacting surface of at least one of the staple cartridge assembly or the anvil assembly during a staple firing,wherein the staple line reinforcement material includes a plurality of perforations positioned adjacent to the plurality of attachment members and configured to facilitate separation of the second portion of the staple line reinforcement material from the first portion of the staple line reinforcement material at the plurality of perforations.
  • 9. The surgical stapling instrument according to claim 8, wherein the plurality of rows of staple receiving slots and the plurality of rows of staple forming recesses are arranged in an annular array, such that the plurality of attachment members are disposed in the same annular row.
  • 10. The surgical stapling instrument according to claim 9, wherein the plurality of perforations define a circular ring in the staple line reinforcement material.
  • 11. The surgical stapling instrument according to claim 10, wherein the circular ring formed by the plurality of perforations is radially inward relative to the annular row in which the plurality of attachment members are disposed.
  • 12. The surgical stapling instrument according to claim 9, wherein the annular row in which the plurality of attachment members are disposed is the outermost annular row of the plurality of rows in at least one of the cartridge assembly or the anvil assembly.
  • 13. The surgical stapling instrument according to claim 9, wherein at least one row of the plurality of rows in at least one of the cartridge assembly or the anvil assembly is devoid of attachment members.
  • 14. The surgical stapling instrument according to claim 1, wherein each of the first and second elongate attachment members is flush with the tissue contacting surface of the at least one of the staple cartridge assembly or the anvil assembly.
  • 15. The surgical stapling instrument according to claim 1, wherein each of the first and second elongate attachment members is configured to be positioned between a bottom surface of the staple line reinforcement material and the tissue contacting surface of the at least one of the staple cartridge assembly or the anvil assembly.
  • 16. The surgical stapling instrument according to claim 8, wherein the plurality of attachment members is fabricated from a polymeric material.
  • 17. The surgical stapling instrument according to claim 16, wherein the tissue contacting surface of the anvil assembly or the staple cartridge assembly defines a recess located at one of the gaps, the first or second elongate attachment members being overmolded into the recess located at one of the gaps.
CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a Continuation Application claiming the benefit of and priority to U.S. patent application Ser. No. 15/896,683, filed on Feb. 14, 2018, which is a Continuation Application claiming the benefit of and priority to U.S. patent application Ser. No. 14/682,331, filed on Apr. 9, 2015, which is a Continuation Application claiming the benefit of and priority to U.S. patent application Ser. No. 14/331,537, filed on Jul. 15, 2014 (now U.S. Pat. No. 9,016,544), which is a Continuation Application claiming the benefit of and priority to U.S. patent application Ser. No. 13/094,893, filed on Apr. 27, 2011 (now U.S. Pat. No. 8,789,737), the entire contents of each of which are incorporated herein by reference.

US Referenced Citations (558)
Number Name Date Kind
3054406 Usher Sep 1962 A
3124136 Usher Mar 1964 A
3499591 Green Mar 1970 A
3797494 Zaffaroni Mar 1974 A
4347847 Usher Sep 1982 A
4354628 Green Oct 1982 A
4452245 Usher Jun 1984 A
4527724 Chow Jul 1985 A
4605730 Shalaby et al. Aug 1986 A
4655221 Devereux Apr 1987 A
4834090 Moore May 1989 A
4838884 Dumican et al. Jun 1989 A
4927640 Dahlinder et al. May 1990 A
4930674 Barak Jun 1990 A
5002551 Linsky et al. Mar 1991 A
5014899 Presty et al. May 1991 A
5040715 Green et al. Aug 1991 A
5065929 Schulze et al. Nov 1991 A
5112496 Dhawan et al. May 1992 A
5142933 Kelley Sep 1992 A
5205459 Brinkerhoff et al. Apr 1993 A
5263629 Trumbull Nov 1993 A
5281197 Arias et al. Jan 1994 A
5308576 Green et al. May 1994 A
5314471 Brauker et al. May 1994 A
5344454 Clarke et al. Sep 1994 A
5392979 Green et al. Feb 1995 A
5397324 Carroll et al. Mar 1995 A
5405072 Zlock et al. Apr 1995 A
5425745 Green et al. Jun 1995 A
5441193 Gravener Aug 1995 A
5441507 Wilk Aug 1995 A
5443198 Viola et al. Aug 1995 A
5468253 Bezwada et al. Nov 1995 A
5497933 DeFonzo Mar 1996 A
5503638 Cooper et al. Apr 1996 A
5542594 McKean et al. Aug 1996 A
5549628 Cooper et al. Aug 1996 A
5575803 Cooper et al. Nov 1996 A
5645915 Kranzler et al. Jul 1997 A
5651491 Heaton Jul 1997 A
5653756 Clarke et al. Aug 1997 A
5683809 Freeman et al. Nov 1997 A
5690675 Sawyer et al. Nov 1997 A
5702409 Rayburn et al. Dec 1997 A
5752965 Francis et al. May 1998 A
5762256 Mastri et al. Jun 1998 A
5766188 Igaki Jun 1998 A
5769892 Kingwell Jun 1998 A
5782396 Mastri et al. Jul 1998 A
5799857 Robertson et al. Sep 1998 A
5810855 Rayburn et al. Sep 1998 A
5814057 Oi et al. Sep 1998 A
5833695 Yoon Nov 1998 A
5843096 Igaki et al. Dec 1998 A
5871135 Williamson IV et al. Feb 1999 A
5895412 Tucker Apr 1999 A
5902312 Frater et al. May 1999 A
5908427 McKean et al. Jun 1999 A
5915616 Viola et al. Jun 1999 A
5931847 Bittner et al. Aug 1999 A
5957363 Heck Sep 1999 A
5964774 McKean et al. Oct 1999 A
5997895 Narotam et al. Dec 1999 A
6019791 Wood Feb 2000 A
6030392 Dakov Feb 2000 A
6032849 Mastri et al. Mar 2000 A
6045560 McKean et al. Apr 2000 A
6063097 Oi et al. May 2000 A
6080169 Turtel Jun 2000 A
6099551 Gabbay Aug 2000 A
6142933 Longo et al. Nov 2000 A
6149667 Hovland et al. Nov 2000 A
6155265 Hammerslag Dec 2000 A
6210439 Firmin et al. Apr 2001 B1
6214020 Mulhauser et al. Apr 2001 B1
6241139 Milliman et al. Jun 2001 B1
6258107 Balazs et al. Jul 2001 B1
6267772 Mulhauser et al. Jul 2001 B1
6270530 Eldridge et al. Aug 2001 B1
6273897 Dalessandro et al. Aug 2001 B1
6280453 Kugel et al. Aug 2001 B1
6299631 Shalaby Oct 2001 B1
6312457 DiMatteo et al. Nov 2001 B1
6312474 Francis et al. Nov 2001 B1
6325810 Hamilton et al. Dec 2001 B1
6398797 Bombard et al. Jun 2002 B2
6436030 Rehil Aug 2002 B2
6454780 Wallace Sep 2002 B1
6461368 Fogarty et al. Oct 2002 B2
6503257 Grant et al. Jan 2003 B2
6514283 DiMatteo et al. Feb 2003 B2
6517566 Hovland et al. Feb 2003 B1
6551356 Rousseau Apr 2003 B2
6568398 Cohen May 2003 B2
6592597 Grant et al. Jul 2003 B2
6610006 Amid et al. Aug 2003 B1
6638285 Gabbay Oct 2003 B2
6652594 Francis et al. Nov 2003 B2
6656193 Grant et al. Dec 2003 B2
6669735 Pelissier Dec 2003 B1
6677258 Carroll et al. Jan 2004 B2
6685714 Rousseau Feb 2004 B2
6704210 Myers Mar 2004 B1
6723114 Shalaby Apr 2004 B2
6726706 Dominguez Apr 2004 B2
6736823 Darois et al. May 2004 B2
6736854 Vadurro et al. May 2004 B2
6746458 Cloud Jun 2004 B1
6773458 Brauker et al. Aug 2004 B1
6927315 Heinecke et al. Aug 2005 B1
7025772 Gellman et al. Apr 2006 B2
7128748 Mooradian et al. Oct 2006 B2
7134438 Makower et al. Nov 2006 B2
7147138 Shelton, IV Dec 2006 B2
7179268 Roy et al. Feb 2007 B2
7210810 Iversen et al. May 2007 B1
7434717 Shelton, IV et al. Oct 2008 B2
7438209 Hess et al. Oct 2008 B1
7547312 Bauman et al. Jun 2009 B2
7559937 de la Torre et al. Jul 2009 B2
7571845 Viola Aug 2009 B2
7604151 Hess et al. Oct 2009 B2
7665646 Prommersberger Feb 2010 B2
7669747 Weisenburgh, II et al. Mar 2010 B2
7717313 Criscuolo et al. May 2010 B2
7722642 Williamson, IV et al. May 2010 B2
7744627 Orban, III et al. Jun 2010 B2
7776060 Mooradian et al. Aug 2010 B2
7789889 Zubik et al. Sep 2010 B2
7793813 Bettuchi Sep 2010 B2
7799026 Schechter et al. Sep 2010 B2
7823592 Bettuchi et al. Nov 2010 B2
7845533 Marczyk et al. Dec 2010 B2
7845536 Viola Dec 2010 B2
7846149 Jankowski Dec 2010 B2
7909224 Prommersberger Mar 2011 B2
7938307 Bettuchi May 2011 B2
7950561 Aranyi May 2011 B2
7951166 Orban, III et al. May 2011 B2
7967179 Olson et al. Jun 2011 B2
7988027 Olson et al. Aug 2011 B2
8011550 Aranyi et al. Sep 2011 B2
8016177 Bettuchi et al. Sep 2011 B2
8016178 Olson et al. Sep 2011 B2
8025199 Whitman et al. Sep 2011 B2
8028883 Stopek Oct 2011 B2
8033983 Chu et al. Oct 2011 B2
8038045 Bettuchi Oct 2011 B2
8062330 Prommersberger et al. Nov 2011 B2
8083119 Prommersberger Dec 2011 B2
8123766 Bauman et al. Feb 2012 B2
8123767 Bauman et al. Feb 2012 B2
8127975 Olson et al. Mar 2012 B2
8133336 Kettlewell et al. Mar 2012 B2
8133559 Lee et al. Mar 2012 B2
8146791 Bettuchi et al. Apr 2012 B2
8157149 Olson et al. Apr 2012 B2
8157151 Ingmanson et al. Apr 2012 B2
8167895 D'Agostino et al. May 2012 B2
8178746 Hildeberg et al. May 2012 B2
8192460 Orban, III et al. Jun 2012 B2
8210414 Bettuchi et al. Jul 2012 B2
8225799 Bettuchi Jul 2012 B2
8225981 Criscuolo et al. Jul 2012 B2
8231043 Tarinelli et al. Jul 2012 B2
8235273 Olson et al. Aug 2012 B2
8245901 Stopek Aug 2012 B2
8256654 Bettuchi et al. Sep 2012 B2
8257391 Orban, III et al. Sep 2012 B2
8276800 Bettuchi Oct 2012 B2
8286849 Bettuchi Oct 2012 B2
8308042 Aranyi Nov 2012 B2
8308045 Bettuchi et al. Nov 2012 B2
8308046 Prommersberger Nov 2012 B2
8312885 Bettuchi et al. Nov 2012 B2
8313014 Bettuchi Nov 2012 B2
8322590 Patel et al. Dec 2012 B2
8348126 Olson et al. Jan 2013 B2
8348130 Shah et al. Jan 2013 B2
8365972 Aranyi et al. Feb 2013 B2
8371491 Huitema et al. Feb 2013 B2
8371492 Aranyi et al. Feb 2013 B2
8371493 Aranyi et al. Feb 2013 B2
8393514 Shelton, IV et al. Mar 2013 B2
8393517 Milo Mar 2013 B2
8408440 Olson et al. Apr 2013 B2
8413869 Heinrich Apr 2013 B2
8413871 Racenet et al. Apr 2013 B2
8424742 Bettuchi Apr 2013 B2
8453652 Stopek Jun 2013 B2
8453904 Eskaros et al. Jun 2013 B2
8453909 Olson et al. Jun 2013 B2
8453910 Bettuchi et al. Jun 2013 B2
8464925 Hull et al. Jun 2013 B2
8474677 Woodard, Jr. et al. Jul 2013 B2
8479968 Hodgkinson Jul 2013 B2
8485414 Criscuolo et al. Jul 2013 B2
8496683 Prommersberger et al. Jul 2013 B2
8511533 Viola et al. Aug 2013 B2
8512402 Marczyk et al. Aug 2013 B2
8529600 Woodard, Jr. et al. Sep 2013 B2
8540131 Swayze Sep 2013 B2
8551138 Orban, III et al. Oct 2013 B2
8551596 Chou Oct 2013 B2
8556918 Bauman et al. Oct 2013 B2
8561873 Ingmanson et al. Oct 2013 B2
8579990 Priewe Nov 2013 B2
8584920 Hodgkinson Nov 2013 B2
8590762 Hess et al. Nov 2013 B2
8616430 Stopek et al. Dec 2013 B2
8631989 Aranyi et al. Jan 2014 B2
8646674 Schulte et al. Feb 2014 B2
8668129 Olson Mar 2014 B2
8684250 Bettuchi et al. Apr 2014 B2
8721703 Fowler May 2014 B2
8789737 Hodgkinson et al. Jul 2014 B2
8814888 Sgro Aug 2014 B2
8857694 Shelton, IV et al. Oct 2014 B2
8864009 Shelton, IV et al. Oct 2014 B2
8920443 Hiles et al. Dec 2014 B2
8920444 Hiles et al. Dec 2014 B2
8956390 Shah et al. Feb 2015 B2
9005243 Stopek Apr 2015 B2
9016544 Hodgkinson et al. Apr 2015 B2
9027817 Milliman et al. May 2015 B2
9044227 Shelton, IV et al. Jun 2015 B2
9055944 Hodgkinson et al. Jun 2015 B2
9084602 Gleiman Jul 2015 B2
9107665 Hodgkinson et al. Aug 2015 B2
9107667 Hodgkinson Aug 2015 B2
9113873 Marczyk et al. Aug 2015 B2
9113885 Hodgkinson et al. Aug 2015 B2
9113893 Sorrentino et al. Aug 2015 B2
9161753 Prior Oct 2015 B2
9161757 Bettuchi Oct 2015 B2
9186140 Hiles et al. Nov 2015 B2
9186144 Stevenson et al. Nov 2015 B2
9192378 Aranyi et al. Nov 2015 B2
9192379 Aranyi et al. Nov 2015 B2
9192380 Racenet et al. Nov 2015 B2
9192383 Milliman Nov 2015 B2
9192384 Bettuchi Nov 2015 B2
9198660 Hodgkinson Dec 2015 B2
9198663 Marczyk et al. Dec 2015 B1
9204881 Penna Dec 2015 B2
9220504 Viola et al. Dec 2015 B2
9226754 D'Agostino et al. Jan 2016 B2
9237892 Hodgkinson Jan 2016 B2
9237893 Carter et al. Jan 2016 B2
9277922 Carter et al. Mar 2016 B2
9295466 Hodgkinson et al. Mar 2016 B2
9326773 Casasanta, Jr. et al. May 2016 B2
9328111 Zhou et al. May 2016 B2
9345479 Racenet et al. May 2016 B2
9351729 Orban, III et al. May 2016 B2
9351731 Carter et al. May 2016 B2
9351732 Hodgkinson May 2016 B2
9358005 Shelton, IV et al. Jun 2016 B2
9364229 D'Agostino et al. Jun 2016 B2
9364234 Stopek et al. Jun 2016 B2
9393018 Wang et al. Jul 2016 B2
9402627 Stevenson et al. Aug 2016 B2
9414839 Penna Aug 2016 B2
9433412 Bettuchi et al. Sep 2016 B2
9433413 Stopek Sep 2016 B2
9433420 Hodgkinson Sep 2016 B2
9445812 Olson et al. Sep 2016 B2
9445817 Bettuchi Sep 2016 B2
9486215 Olson et al. Nov 2016 B2
9504470 Milliman Nov 2016 B2
9572576 Hodgkinson et al. Feb 2017 B2
9597077 Hodgkinson Mar 2017 B2
9610080 Whitfield et al. Apr 2017 B2
9622745 Ingmanson et al. Apr 2017 B2
9629626 Soltz et al. Apr 2017 B2
9655620 Prescott et al. May 2017 B2
9675351 Hodgkinson et al. Jun 2017 B2
9681936 Hodgkinson et al. Jun 2017 B2
9693772 Ingmanson et al. Jul 2017 B2
9775617 Carter et al. Oct 2017 B2
9775618 Bettuchi et al. Oct 2017 B2
9782173 Mozdzierz Oct 2017 B2
9844378 Casasanta et al. Dec 2017 B2
9931116 Racenet et al. Apr 2018 B2
9974542 Hodgkinson May 2018 B2
10022125 Stopek et al. Jul 2018 B2
10098639 Hodgkinson Oct 2018 B2
10111659 Racenet et al. Oct 2018 B2
10154840 Viola et al. Dec 2018 B2
10327772 Olson Jun 2019 B2
10357249 Carter Jul 2019 B2
10485540 Hodgkinson Nov 2019 B2
10695066 Casasanta Jun 2020 B2
10842485 Hodgkinson Nov 2020 B2
20020016626 DiMatteo et al. Feb 2002 A1
20020019187 Carroll et al. Feb 2002 A1
20020028243 Masters Mar 2002 A1
20020052622 Rousseau May 2002 A1
20020091397 Chen Jul 2002 A1
20020133236 Rousseau Sep 2002 A1
20020138152 Francis et al. Sep 2002 A1
20020151911 Gabbay Oct 2002 A1
20020165559 Grant Nov 2002 A1
20020165562 Grant et al. Nov 2002 A1
20020165563 Grant Nov 2002 A1
20020177859 Monassevitch et al. Nov 2002 A1
20030065345 Weadock Apr 2003 A1
20030065346 Evens et al. Apr 2003 A1
20030083676 Wallace May 2003 A1
20030088256 Conston et al. May 2003 A1
20030105510 DiMatteo et al. Jun 2003 A1
20030114866 Ulmsten et al. Jun 2003 A1
20030120284 Palacios et al. Jun 2003 A1
20030125676 Swenson et al. Jul 2003 A1
20030167064 Whayne Sep 2003 A1
20030181927 Wallace Sep 2003 A1
20030183671 Mooradian et al. Oct 2003 A1
20030196668 Harrison et al. Oct 2003 A1
20030208231 Williamson et al. Nov 2003 A1
20040034377 Sharkawy et al. Feb 2004 A1
20040092912 Jinno et al. May 2004 A1
20040092960 Abrams et al. May 2004 A1
20040093029 Zubik et al. May 2004 A1
20040107006 Francis et al. Jun 2004 A1
20040116945 Sharkawy et al. Jun 2004 A1
20040131418 Budde et al. Jul 2004 A1
20040142621 Carroll et al. Jul 2004 A1
20040172048 Browning Sep 2004 A1
20040209059 Foss Oct 2004 A1
20040215214 Crews et al. Oct 2004 A1
20040215219 Eldridge et al. Oct 2004 A1
20040215221 Suyker et al. Oct 2004 A1
20040232201 Wenchell et al. Nov 2004 A1
20040254590 Hoffman et al. Dec 2004 A1
20040260315 Dell et al. Dec 2004 A1
20050002981 Lahtinen et al. Jan 2005 A1
20050021026 Baily Jan 2005 A1
20050021053 Heinrich Jan 2005 A1
20050021085 Abrams et al. Jan 2005 A1
20050059996 Bauman et al. Mar 2005 A1
20050059997 Bauman et al. Mar 2005 A1
20050070929 Dalessandro et al. Mar 2005 A1
20050107805 Bouffier May 2005 A1
20050118435 DeLucia et al. Jun 2005 A1
20050143756 Jankowski Jun 2005 A1
20050149073 Arani et al. Jul 2005 A1
20050228446 Mooradian et al. Oct 2005 A1
20050245965 Orban, III et al. Nov 2005 A1
20050283256 Sommerich et al. Dec 2005 A1
20060004407 Hiles et al. Jan 2006 A1
20060025816 Shelton Feb 2006 A1
20060085030 Bettuchi et al. Apr 2006 A1
20060085034 Bettuchi Apr 2006 A1
20060135992 Bettuchi et al. Jun 2006 A1
20060135995 Ruff et al. Jun 2006 A1
20060173470 Oray et al. Aug 2006 A1
20060178683 Shimoji et al. Aug 2006 A1
20060190027 Downey Aug 2006 A1
20060212050 D'Agostino et al. Sep 2006 A1
20060219752 Arad et al. Oct 2006 A1
20060271104 Viola et al. Nov 2006 A1
20070026031 Bauman et al. Feb 2007 A1
20070034669 de la Torre et al. Feb 2007 A1
20070049953 Shimoji et al. Mar 2007 A2
20070123839 Rousseau et al. May 2007 A1
20070179528 Soltz et al. Aug 2007 A1
20070203509 Bettuchi Aug 2007 A1
20070203510 Bettuchi Aug 2007 A1
20070246505 Pace-Floridia et al. Oct 2007 A1
20080009811 Cantor Jan 2008 A1
20080029570 Shelton et al. Feb 2008 A1
20080082126 Murray et al. Apr 2008 A1
20080110959 Orban et al. May 2008 A1
20080125812 Zubik et al. May 2008 A1
20080140115 Stopek Jun 2008 A1
20080161831 Bauman et al. Jul 2008 A1
20080161832 Bauman et al. Jul 2008 A1
20080169327 Shelton et al. Jul 2008 A1
20080169328 Shelton Jul 2008 A1
20080169329 Shelton et al. Jul 2008 A1
20080169330 Shelton et al. Jul 2008 A1
20080169331 Shelton et al. Jul 2008 A1
20080169332 Shelton et al. Jul 2008 A1
20080169333 Shelton et al. Jul 2008 A1
20080200949 Hiles et al. Aug 2008 A1
20080216855 Nasca Sep 2008 A1
20080290134 Bettuchi et al. Nov 2008 A1
20080308608 Prommersberger Dec 2008 A1
20080314960 Marczyk et al. Dec 2008 A1
20090001121 Hess et al. Jan 2009 A1
20090001122 Prommersberger et al. Jan 2009 A1
20090001123 Morgan et al. Jan 2009 A1
20090001124 Hess et al. Jan 2009 A1
20090001125 Hess et al. Jan 2009 A1
20090001126 Hess et al. Jan 2009 A1
20090001128 Weisenburgh, II et al. Jan 2009 A1
20090001130 Hess et al. Jan 2009 A1
20090005808 Hess et al. Jan 2009 A1
20090030452 Bauman et al. Jan 2009 A1
20090031842 Kawai et al. Feb 2009 A1
20090043334 Bauman et al. Feb 2009 A1
20090076510 Bell et al. Mar 2009 A1
20090076528 Sgro Mar 2009 A1
20090078739 Viola Mar 2009 A1
20090095791 Eskaros et al. Apr 2009 A1
20090095792 Bettuchi Apr 2009 A1
20090120994 Murray et al. May 2009 A1
20090134200 Tarinelli et al. May 2009 A1
20090206125 Huitema et al. Aug 2009 A1
20090206126 Huitema et al. Aug 2009 A1
20090206139 Hall et al. Aug 2009 A1
20090206141 Huitema et al. Aug 2009 A1
20090206142 Huitema et al. Aug 2009 A1
20090206143 Huitema et al. Aug 2009 A1
20090218384 Aranyi Sep 2009 A1
20090277944 Dalessandro et al. Nov 2009 A9
20090277947 Viola Nov 2009 A1
20090287230 D'Agostino et al. Nov 2009 A1
20100012704 Tarinelli Racenet et al. Jan 2010 A1
20100016855 Ramstein et al. Jan 2010 A1
20100065606 Stopek Mar 2010 A1
20100065607 Orban, III et al. Mar 2010 A1
20100072254 Aranyi et al. Mar 2010 A1
20100147921 Olson Jun 2010 A1
20100147922 Olson Jun 2010 A1
20100147923 D'Agostino et al. Jun 2010 A1
20100174253 Cline et al. Jul 2010 A1
20100243707 Olson et al. Sep 2010 A1
20100243708 Aranyi et al. Sep 2010 A1
20100243711 Olson et al. Sep 2010 A1
20100249805 Olson et al. Sep 2010 A1
20100264195 Bettuchi Oct 2010 A1
20100282815 Bettuchi et al. Nov 2010 A1
20100331859 Omori Dec 2010 A1
20100331880 Stopek Dec 2010 A1
20110024476 Bettuchi et al. Feb 2011 A1
20110024481 Bettuchi et al. Feb 2011 A1
20110034910 Ross et al. Feb 2011 A1
20110036894 Bettuchi Feb 2011 A1
20110042442 Viola et al. Feb 2011 A1
20110046650 Bettuchi Feb 2011 A1
20110057016 Bettuchi Mar 2011 A1
20110087279 Shah et al. Apr 2011 A1
20110089220 Ingmanson et al. Apr 2011 A1
20110125138 Malinouskas et al. May 2011 A1
20110166673 Patel et al. Jul 2011 A1
20110168759 Prommersberger Jul 2011 A1
20110278346 Hull et al. Nov 2011 A1
20110278347 Olson et al. Nov 2011 A1
20120080484 Morgan et al. Apr 2012 A1
20120083723 Vitaris et al. Apr 2012 A1
20120145767 Shah et al. Jun 2012 A1
20120187179 Gleiman Jul 2012 A1
20120197272 Oray et al. Aug 2012 A1
20120228360 Hodgkinson et al. Sep 2012 A1
20120241491 Aldridge et al. Sep 2012 A1
20120253298 Henderson et al. Oct 2012 A1
20120273547 Hodgkinson et al. Nov 2012 A1
20120289979 Eskaros et al. Nov 2012 A1
20130037596 Bear et al. Feb 2013 A1
20130075446 Wang et al. Mar 2013 A1
20130105548 Hodgkinson et al. May 2013 A1
20130105553 Racenet et al. May 2013 A1
20130112731 Hodgkinson May 2013 A1
20130112732 Aranyi et al. May 2013 A1
20130112733 Aranyi et al. May 2013 A1
20130146643 Schmid et al. Jun 2013 A1
20130153633 Casasanta, Jr. et al. Jun 2013 A1
20130153634 Carter et al. Jun 2013 A1
20130153635 Hodgkinson Jun 2013 A1
20130153638 Carter et al. Jun 2013 A1
20130153639 Hodgkinson et al. Jun 2013 A1
20130153640 Hodgkinson Jun 2013 A1
20130181031 Olson et al. Jul 2013 A1
20130193186 Racenet et al. Aug 2013 A1
20130193190 Carter et al. Aug 2013 A1
20130193191 Stevenson et al. Aug 2013 A1
20130193192 Casasanta, Jr. et al. Aug 2013 A1
20130209659 Racenet et al. Aug 2013 A1
20130214030 Aronhalt et al. Aug 2013 A1
20130221062 Hodgkinson Aug 2013 A1
20130221063 Aronhalt et al. Aug 2013 A1
20130221064 Aronhalt et al. Aug 2013 A1
20130221065 Aronhalt et al. Aug 2013 A1
20130240600 Bettuchi Sep 2013 A1
20130240601 Bettuchi et al. Sep 2013 A1
20130240602 Stopek Sep 2013 A1
20130256373 Schmid et al. Oct 2013 A1
20130256380 Schmid et al. Oct 2013 A1
20130277411 Hodgkinson et al. Oct 2013 A1
20130306707 Viola et al. Nov 2013 A1
20130310873 Stopek et al. Nov 2013 A1
20130327807 Olson et al. Dec 2013 A1
20140012317 Orban et al. Jan 2014 A1
20140021242 Hodgkinson et al. Jan 2014 A1
20140027490 Marczyk et al. Jan 2014 A1
20140034704 Ingmanson et al. Feb 2014 A1
20140048580 Merchant et al. Feb 2014 A1
20140061280 Ingmanson et al. Mar 2014 A1
20140061281 Hodgkinson Mar 2014 A1
20140224686 Aronhalt et al. Aug 2014 A1
20150001276 Hodgkinson et al. Jan 2015 A1
20150122872 Olson et al. May 2015 A1
20150133995 Shelton, IV et al. May 2015 A1
20150164503 Stevenson et al. Jun 2015 A1
20150164506 Carter et al. Jun 2015 A1
20150164507 Carter et al. Jun 2015 A1
20150196297 Stopek et al. Jul 2015 A1
20150209033 Hodgkinson Jul 2015 A1
20150209045 Hodgkinson et al. Jul 2015 A1
20150209048 Carter et al. Jul 2015 A1
20150231409 Racenet et al. Aug 2015 A1
20150305743 Casasanta et al. Oct 2015 A1
20150327864 Hodgkinson et al. Nov 2015 A1
20160022268 Prior Jan 2016 A1
20160045200 Milliman Feb 2016 A1
20160058451 Racenet et al. Mar 2016 A1
20160100834 Viola et al. Apr 2016 A1
20160106430 Carter et al. Apr 2016 A1
20160113647 Hodgkinson Apr 2016 A1
20160128694 Baxter, III et al. May 2016 A1
20160157857 Hodgkinson et al. Jun 2016 A1
20160174988 D'Agostino et al. Jun 2016 A1
20160206315 Olson Jul 2016 A1
20160220257 Casasanta et al. Aug 2016 A1
20160249923 Hodgkinson et al. Sep 2016 A1
20160256166 Stopek et al. Sep 2016 A1
20160270793 Carter et al. Sep 2016 A1
20160310143 Bettuchi Oct 2016 A1
20160338704 Penna Nov 2016 A1
20160367252 Olson et al. Dec 2016 A1
20160367253 Hodgkinson Dec 2016 A1
20160367257 Stevenson et al. Dec 2016 A1
20170042540 Olson et al. Feb 2017 A1
20170049452 Milliman Feb 2017 A1
20170086845 Vendely Mar 2017 A1
20170119390 Schellin et al. May 2017 A1
20170150967 Hodgkinson et al. Jun 2017 A1
20170172575 Hodgkinson Jun 2017 A1
20170231629 Stopek et al. Aug 2017 A1
20170238931 Prescott et al. Aug 2017 A1
20170281328 Hodgkinson et al. Oct 2017 A1
20170296188 Ingmanson et al. Oct 2017 A1
20170354415 Casasanta, Jr. et al. Dec 2017 A1
20180125491 Aranyi May 2018 A1
20180140301 Milliman May 2018 A1
20180168654 Hodgkinson et al. Jun 2018 A1
20180214147 Merchant et al. Aug 2018 A1
20180229054 Racenet et al. Aug 2018 A1
20180235621 Shelton, IV Aug 2018 A1
20180250000 Hodgkinson et al. Sep 2018 A1
20180256164 Aranyi Sep 2018 A1
20180296214 Hodgkinson et al. Oct 2018 A1
20180310937 Stopek et al. Nov 2018 A1
20190021734 Hodgkinson Jan 2019 A1
20190059878 Racenet et al. Feb 2019 A1
20190083087 Viola et al. Mar 2019 A1
Foreign Referenced Citations (67)
Number Date Country
2282761 Sep 1998 CA
2596254 Aug 2006 CA
101310680 Nov 2008 CN
101332110 Dec 2008 CN
1602563 Mar 1950 DE
19924311 Nov 2000 DE
0327022 Aug 1989 EP
0594148 Apr 1994 EP
0667119 Aug 1995 EP
1064883 Jan 2001 EP
1256317 Nov 2002 EP
1520525 Apr 2005 EP
1621141 Feb 2006 EP
1702570 Sep 2006 EP
1759640 Mar 2007 EP
1815804 Aug 2007 EP
1825820 Aug 2007 EP
1929958 Jun 2008 EP
1994890 Nov 2008 EP
2005894 Dec 2008 EP
2005895 Dec 2008 EP
2039308 Mar 2009 EP
2090231 Aug 2009 EP
2090244 Aug 2009 EP
2090252 Aug 2009 EP
2163211 Mar 2010 EP
2189121 May 2010 EP
2198787 Jun 2010 EP
2236098 Oct 2010 EP
2258282 Dec 2010 EP
2311386 Apr 2011 EP
2462880 Jun 2012 EP
2491867 Aug 2012 EP
2497431 Sep 2012 EP
2517637 Oct 2012 EP
2586380 May 2013 EP
2620106 Jul 2013 EP
2630922 Aug 2013 EP
2644125 Oct 2013 EP
2008595 Apr 2016 EP
2000166933 Jun 2000 JP
2001502575 Feb 2001 JP
2002202213 Jul 2002 JP
2007124166 May 2007 JP
9005489 May 1990 WO
9516221 Jun 1995 WO
9622055 Jul 1996 WO
9701989 Jan 1997 WO
9713463 Apr 1997 WO
9817180 Apr 1998 WO
9838923 Sep 1998 WO
9945849 Sep 1999 WO
03082126 Oct 2003 WO
03088845 Oct 2003 WO
03094743 Nov 2003 WO
03105698 Dec 2003 WO
2005079675 Sep 2005 WO
2006023578 Mar 2006 WO
2006044490 Apr 2006 WO
2006083748 Aug 2006 WO
2007121579 Nov 2007 WO
2008057281 May 2008 WO
2008109125 Sep 2008 WO
2010075298 Jul 2010 WO
2011143183 Nov 2011 WO
WO-2011143183 Nov 2011 WO
2012044848 Apr 2012 WO
Non-Patent Literature Citations (156)
Entry
Australian Examination Report No. 1 corresponding to AU 2014200584 dated Jun. 15, 2015.
European Office Action corresponding to EP 13 180 881.8 dated Jun. 19, 2015.
European Office Action corresponding to EP 14 157 195.0 dated Jul. 2, 2015.
Extended European Search Report corresponding to EP 12 19 6902.6 dated Aug. 6, 2015.
Extended European Search Report corresponding to EP 14 15 2060.1 dated Aug. 14, 2015.
Chinese Notification of Reexamination corresponding to CN 201010517292.8 dated Jun. 2, 2015.
Japanese Office Action corresponding to JP 2014-216989 dated Sep. 11, 2015.
Canadian First Office Action corresponding to CA 2,686,105 dated Sep. 17, 2015.
Japanese Office Action corresponding to JP 2012-040188 dated Oct. 21, 2015.
European Communication corresponding to EP 13 17 6895.4 dated Nov. 5, 2015.
Chinese First Office Action corresponding to CN 201210544552 dated Nov. 23, 2015.
Chinese First Office Action corresponding to CN 201210545228 dated Nov. 30, 2015.
Extended European Search Report corresponding to EP 15 18 0491.1 dated Dec. 9, 2015.
Extended European Search Report corresponding to EP 15 18 3819.0 dated Dec. 11, 2015.
Canadian Office Action corresponding to CA 2,697,819 dated Jan. 6, 2016.
Canadian Office Action corresponding to CA 2,696,419 dated Jan. 14, 2016.
European Office Action corresponding to EP 12 19 8776.2 dated Jan. 19, 2016.
Extended European Search Report corresponding to EP 15 17 4146.9 dated Jan. 20, 2016.
Chinese First Office Action corresponding to CN 201310353628.5 dated Jan. 25, 2016.
Extended European Search Report corresponding to EP 12 19 6912.5 dated Feb. 1, 2016.
Japanese Office Action corresponding to JP 2012-098903 dated Feb. 22, 2016.
Extended European Search Report corresponding to EP 12 19 8753.1 dated Feb. 24, 2016.
Chinese First Office Action corresponding to CN 201410449019.4 dated Mar. 30, 2016.
Extended European Search Report corresponding to EP 16 15 0232.3 dated Apr. 12, 2016.
European Office Action corresponding to EP 11 18 3256.4 dated Apr. 20, 2016.
Australian Examination Report No. 1 corresponding to AU 2012244169 dated May 10, 2016.
European Office Action corresponding to EP 10 25 0715.9 dated May 12, 2016.
Chinese First Office Action corresponding to CN 201410778512.0 dated May 13, 2016.
Australian Examination Report No. 1 corresponding to AU 2012227358 dated May 16, 2016.
Japanese Office Action corresponding to JP 2012-040188 dated May 17, 2016.
Australian Examination Report No. 1 corresponding to AU 2012244380 dated May 20, 2016.
Australian Examination Report No. 1 corresponding to AU 2014227480 dated May 21, 2016.
Australian Examination Report No. 1 corresponding to AU 2012254977 dated May 30, 2016.
Extended European Search Report corresponding to EP 16 15 3647.9 dated Jun. 3, 2016.
European Communication, dated Aug. 5, 2016, corresponding to European Application No. 12 165 609.4; 4 pages.
European Office Action corresponding to EP 14 17 2681.0 dated May 13, 2016.
Chinese Office Action corresponding to CN 201210545228 dated Jun. 29, 2016.
Japanese Office Action corresponding to JP 2012-250058 dated Jun. 29, 2016.
European Office Action corresponding to EP 14 15 7997.9 dated Jun. 29, 2016.
Canadian Office Action corresponding to CA 2,712,617 dated Jun. 30, 2016.
Chinese First Office Action corresponding to CN 2013103036903 dated Jun. 30, 2016.
Australian Patent Examination Report No. 1 corresponding to AU 2012250278 dated Jul. 10, 2016.
Australian Patent Examination Report No. 1 corresponding to AU 2012244382 dated Jul. 10, 2016.
Japanese Office Action corresponding to 2012-255242 dated Jul. 26, 2016.
Japanese Office Action corresponding to JP 2012-268668 dated Jul. 27, 2016.
European Office Action corresponding to EP 14 15 2060.1 dated Aug. 4, 2016.
European Office Action corresponding to EP 15 15 2392.5 dated Aug. 8, 2016.
Japanese Office Action corresponding to JP 2013-003624 dated Aug. 25, 2016.
Australian Patent Examination Report No. 1 corresponding to AU 2012261752 dated Sep. 6, 2016.
Japanese Office Action corresponding to Patent Application JP 2013-229471 dated May 1, 2018.
Canadian Office Action corresponding to Patent Application CA 2,790,743 dated May 14, 2018.
European Office Action corresponding to Patent Application EP 14 15 7195.0 dated Jun. 12, 2018.
Extended European Search Report corresponding to Patent Application EP 12196912.5 dated Feb. 1, 2016.
Chinese Second Office Action corresponding to Patent Application CN 201610279682.3 dated Aug. 8, 2018.
Chinese Second Office Action corresponding to Patent Application CN 201410588811.8 dated Aug. 27, 2018.
Extended European Search Report corresponding to Patent Application EP 18160809.2 dated Sep. 18, 2018.
Extended European Search Report corresponding to Patent Application EP 18192317.8 dated Dec. 20, 2018.
Extended European Search Report corresponding to Patent Application EP 18190154.7 dated Feb. 4, 2019.
Japanese Office Action corresponding to JP 2014-252703 dated Sep. 26, 2016.
European Office Action corresponding to EP 12 19 8776.2 dated Sep. 12, 2016.
Japanese Office Action corresponding to JP 2013-000321 dated Sep. 13, 2016.
Chinese Second Office Action corresponding to CN 201310353628.5 dated Sep. 26, 2016.
European Office Action corresponding to EP 12 15 2541.4 dated Sep. 27, 2016.
Australian Patent Examination Report No. 1 corresponding to AU 2012268923 dated Sep. 28, 2016.
Chinese First Office Action corresponding to CN 2013107068710 dated Dec. 16, 2016.
Chinese First Office Action corresponding to CN 201310646606.8 dated Dec. 23, 2016.
Japanese Office Action corresponding to JP 2013-000321 dated Jan. 4, 2017.
Extended European Search Report corresponding to EP 16 16 6367.9 dated Jan. 16, 2017.
Australian Examination Report No. 1 corresponding to AU 2013206777 dated Feb. 1, 2017.
Chinese Second Office Action corresponding to CN 2013103036903 dated Feb. 23, 2017.
Japanese Office Action corresponding to JP 2013-175379 dated Mar. 1, 2017.
Chinese First Office Action corresponding to CN 201410028462.4 dated Mar. 2, 2017.
Chinese First Office Action corresponding to CN 201410084070 dated Mar. 13, 2017.
Extended European Search Report corresponding to EP 16 19 6549.6 dated Mar. 17, 2017.
Japanese Office Action corresponding to JP 2013-147701 dated Mar. 21, 2017.
Australian Examination Report No. 1 corresponding to AU 2013206804 dated Mar. 21, 2017.
Australian Examination Report No. 1 corresponding to AU 2013211499 dated May 4, 2017.
Australian Examination Report No. 1 corresponding to AU 2014201008 dated May 23, 2017.
European Office Action corresponding to EP 15 17 4146.9 dated May 15, 2017.
Japanese Office Action corresponding to JP 2013-154561 dated May 23, 2017.
European Office Action corresponding to EP 12 19 4784.0 dated May 29, 2017.
Japanese Office Action corresponding to JP 2013-169083 dated May 31, 2017.
Australian Examination Report No. 1 corresponding to AU 2013213767 dated Jun. 29, 2017.
Australian Examination Report No. 2 corresponding to AU 2012261752 dated Jul. 7, 2017.
Australian Examination Report No. 1 corresponding to AU 2013266989 dated Jul. 10, 2017.
Extended European Search Report corresponding to EP 14 15 3609.4 dated Jul. 14, 2017.
Australian Examination Report No. 1 corresponding to AU 2013234418 dated Jul. 14, 2017.
Extended European Search Report corresponding to EP 14 15 3610.2 dated Jul. 17, 2017.
Australian Examination Report No. 1 corresponding to AU 2014200109 dated Jul. 20, 2017.
Australian Examination Report No. 1 corresponding to AU 2014200074 dated Jul. 20, 2017.
Japanese Office Action corresponding to JP 2013-250857 dated Aug. 17, 2017.
Japanese Office Action corresponding to JP 2013-229471 dated Aug. 17, 2017.
Australian Examination Report No. 1 corresponding to AU 2014200793 dated Sep. 2, 2017.
Extended European Search Report corresponding to EP 17 17 8528.0 dated Oct. 13, 2017.
Australian Examination Report No. 1 corresponding to AU 2013234420 dated Oct. 24, 2017.
Japanese Office Action corresponding to JP 2013-175379 dated Oct. 20, 2017.
Japanese Office Action corresponding to JP 2013-147701 dated Oct. 27, 2017.
Extended European Search Report corresponding to EP 17 17 5656.2 dated Nov. 7, 2017.
Japanese Office Action corresponding to JP 2014-009738 dated Nov. 14, 2017.
European Office Action corresponding to EP 13 17 3986.4 dated Nov. 29, 2017.
Japanese Office Action corresponding to JP 2017-075975 dated Dec. 4, 2017.
European Office Action corresponding to EP 13 19 7958.5 dated Dec. 11, 2017.
Chinese First Office Action corresponding to Patent Application CN 201410588811.8 dated Dec. 5, 2017.
European Office Action corresponding to Patent Application EP 16 16 6367.9 dated Dec. 11, 2017.
Chinese First Office Action corresponding to Patent Application CN 201610279682.3 dated Jan. 10, 2018.
Japanese Office Action corresponding to Patent Application JP 2013-154561 dated Jan. 15, 2018.
Australian Examination Report No. 1 corresponding to Patent Application AU 2017225037 dated Jan. 23, 2018.
International Search Report corresponding to European Application No. EP 11 18 8309.6, completed on Dec. 15, 2011 and dated Jan. 12, 2012;3 pages.
International Search Report corresponding to European Application No. EP 12 15 2229.6, completed on Feb. 23, 2012 and dated Mar. 1, 2012; 4 pages.
International Search Report corresponding to European Application No. EP 12 15 0511.9, completed on Apr. 16, 2012 and dated Apr. 24, 2012; 7 pages.
International Search Report corresponding to European Application No. EP 12 15 2541.4, completed on Apr. 23, 2012 and dated May 3, 2012; 10 pages.
International Search Report corresponding to European Application No. EP 12 15 8861.0, completed on Jul. 17, 2012 and dated Jul. 24, 2012; 9 pages.
International Search Report corresponding to European Application No. EP 12 16 5878.5, completed on Jul. 24, 2012 and dated Aug. 6, 2012; 8 pages.
International Search Report corresponding to European Application No. EP 06 00 4598, completed on Jun. 22, 2006; 2 pages.
International Search Report corresponding to European Application No. EP 06 01 6962.0, completed on Jan. 3, 2007 and dated Jan. 11, 2007; 10 pages.
International Search Report corresponding to International Application No. PCT/US05/36740, completed on Feb. 20, 2007 and dated Mar. 23, 2007; 8 pages.
International Search Report corresponding to International Application No. PCT/US2008/002981, completed on Jun. 9, 2008 and dated Jun. 26, 2008; 2 pages.
International Search Report corresponding to European Application No. EP 08 25 1779, completed on Jul. 14, 2008 and dated Jul. 23, 2008; 5 pages.
International Search Report corresponding to European Application No. EP 08 25 1989.3, completed on Mar. 11, 2010 and dated Mar. 24, 2010; 3 pages.
International Search Report corresponding to European Application No. EP 10 25 0715.9, completed on Jun. 30, 2010 and dated Jul. 20, 2010; 3 pages.
International Search Report corresponding to European Application No. EP 05 80 4382.9, completed on Oct. 5, 2010 and dated Oct. 12, 2010; 3 pages.
International Search Report corresponding to European Application No. EP 10 25 1437.9, completed on Nov. 22, 2010 and dated Dec. 16, 2010; 3 pages.
International Search Report corresponding to European Application No. EP 09 25 2897.5, completed on Feb. 7, 2011 and dated Feb. 15, 2011; 3 pages.
International Search Report corresponding to European Application No. EP 10 25 0642.5, completed on Mar. 25, 2011 and dated Apr. 4, 2011; 4 pages.
Extended European Search Report corresponding to EP No. 12 19 1035.0, completed Jan. 11, 2013 and dated Jan. 18, 2013; 7 pages.
Extended European Search Report corresponding to EP No. 12 18 6175.1, completed Jan. 15, 2013 and dated Jan. 23, 2013; 7 pages.
Extended European Search Report corresponding to EP No. 12 19 1114.3, completed Jan. 23, 2013 and dated Jan. 31, 2013; 10 pages.
Extended European Search Report corresponding to EP No. 12 19 2224.9, completed Mar. 14, 2013 and dated Mar. 26, 2013; 8 pages.
Extended European Search Report corresponding to EP No. 12 19 6911.7, completed Apr. 18, 2013 and dated Apr. 24, 2013; 8 pages.
Extended European Search Report corresponding to EP 12 19 1035.0, completed Jan. 11, 2013 and dated Jan. 18, 2013; 7 pages.
Extended European Search Report corresponding to EP 12 19 6904.2, completed Mar. 28, 2013 and dated Jul. 26, 2013; 8 pages.
Extended European Search Report corresponding to EP 12 19 8749.9, completed May 21, 2013 and dated May 31, 2013; 8 pages.
Extended European Search Report corresponding to EP 07 00 5842.5, completed May 13, 2013 and dated May 29, 2013; 7 pages.
Extended European Search Report corresponding to EP 12 19 8776.2, completed May 16, 2013 and dated May 27, 2013; 8 pages.
Extended European Search Report corresponding to EP 13 15 6297.7, completed Jun. 4, 2013 and dated Jun. 13, 2013; 7 pages.
Extended European Search Report corresponding to EP 13 17 3985.6, completed Aug. 19, 2013 and dated Aug. 28, 2013; 6 pages.
Extended European Search Report corresponding to EP 13 17 3986.4, completed Aug. 20, 2013 and dated Aug. 29, 2013; 7 pages.
Extended European Search Report corresponding to EP 13 17 7437.4, completed Sep. 11, 2013 and dated Sep. 19, 2013; (6 pp).
Extended European Search Report corresponding to EP 13 17 7441.6, completed Sep. 11, 2013 and dated Sep. 19, 2013; (6 pp).
Extended European Search Report corresponding to EP 07 86 1534.1, completed Sep. 20, 2013 and dated Sep. 30, 2013; (5 pp).
Extended European Search Report corresponding to EP 13 18 3876.5, completed Oct. 14, 2013 and dated Oct. 24, 2013; (5 pp).
Extended European Search Report corresponding to EP 13 17 1856.1, completed Oct. 29, 2013 and dated Nov. 7, 2013; (8 pp).
Extended European Search Report corresponding to EP 13 18 0373.6, completed Oct. 31, 2013 and dated Nov. 13, 2013; (7 pp).
Extended European Search Report corresponding to EP 13 18 0881.8, completed Nov. 5, 2013 and dated Nov. 14, 2013; (6 pp).
Extended European Search Report corresponding to EP 13 17 6895.4, completed Nov. 29, 2013 and dated Dec. 12, 2013; (5 pp).
Extended European Search Report corresponding to EP 13 18 2911.1, completed Dec. 2, 2013 and dated Dec. 16, 2013; (8 pp).
Extended European Search Report corresponding to EP 10 25 1795.0, completed Dec. 11, 2013 and dated Dec. 20, 2013; (6 pp).
Extended European Search Report corresponding to EP 13 18 7911.6, completed Jan. 22, 2014 and dated Jan. 31, 2014; (8 pp).
International Search Report corresponding to European Application No. EP 12165609.4, completed on Jul. 5, 2012; 7 pages.
Chinese Second Office Action with English translation, dated Aug. 24, 2015, corresponding to Chinese Patent Application No. 201210129787.2; 19 pages.
European Office Action corresponding to EP 12 198 776.2 dated Apr. 7, 2015.
European Office Action corresponding to EP 13 156 297.7 dated Apr. 10, 2015.
Australian Examination Report No. 1 corresponding to AU 2011250822 dated May 18, 2015.
European Office Action corresponding to EP 12 186 175.1 dated Jun. 1, 2015.
Chinese Office Action corresponding to CN 201010517292.8 dated Jun. 2, 2015.
Extended European Search Report corresponding to EP 14 17 4814.5 dated Jun. 9, 2015.
Related Publications (1)
Number Date Country
20200178965 A1 Jun 2020 US
Continuations (4)
Number Date Country
Parent 15896683 Feb 2018 US
Child 16793129 US
Parent 14682331 Apr 2015 US
Child 15896683 US
Parent 14331537 Jul 2014 US
Child 14682331 US
Parent 13094893 Apr 2011 US
Child 14331537 US